NCT01203592View on ClinicalTrials.gov

Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions

Congenital Myasthenic Syndrome

Interventions

DRUG

Albuterol

4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.

Trial Locations (1)

55905

Mayo Clinic, Rochester